Number of patients

15

Sex

All females

Age (years)

Median 58 (30 - 73)

subtype

Luminal: 7

HER2: 5

Triple negative:3

BSI (Bone Scan Index)

Median 3.028 (0.22 - 12.265)

Duration from bone metastasis diagnosis onset until Sr-89 administration (months)

Median 23 (0 - 51)

Zoledronate and denosumab

Zoledronate: 10 (66.7%)

Denosumab: 4 (26.7%)

No: 1 (6.6%)

Hormonal agents

Yes: 9 (60%)

No: 6 (40%)

Chemotherapeutic agents

Yes: 8 (53.3%)

No: 7 (46.7%)